Shares of Sarepta (SRPT) Therapeutics are up 6% in premarket trading after the company ahead of expected 3-year topline functional results from patients treated in Part 1 of EMBARK, the global, randomized placebo-controlled Phase 3 study evaluating ELEVIDYS in ambulatory individuals with Duchenne muscular dystrophy who were aged four to seven at time of treatment. Sarapeta will host a conference call at 8:30am on Monday, it said.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta sales of Elevidys ‘cratering fast,’ says H.C. Wainwright
- Tempered Growth Outlook and Heightened Regulatory Risk Drive Sell Rating on Sarepta Therapeutics
- Sarepta price target raised to $19 from $18 at BofA
- Balanced Risk Profile Amid Elevidys Uncertainty and PMO Regulatory Headwinds Supports Hold on Sarepta
- Sarepta Therapeutics: Resilient Fundamentals, Elevidys Recovery, and Pipeline Catalysts Underscore Attractive Buy‑Rated Upside